118 related articles for article (PubMed ID: 35869267)
1. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM; Löwenberg B; Manz M; Biemond BJ; Westerweel PE; Klein SK; Fehr M; Sinnige HAM; Efthymiou A; Legdeur MCJC; Pabst T; Gregor M; van der Poel MWM; Deeren D; Tick LW; Jongen-Lavrencic M; van Obbergh F; Boersma RS; de Weerdt O; Chalandon Y; Heim D; Spertini O; van Sluis G; Graux C; Stüssi G; van Norden Y; Ossenkoppele GJ
Leukemia; 2022 Sep; 36(9):2189-2195. PubMed ID: 35869267
[TBL] [Abstract][Full Text] [Related]
2. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
4. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Sweet K; Bhatnagar B; Döhner H; Donnellan W; Frankfurt O; Heuser M; Kota V; Liu H; Raffoux E; Roboz GJ; Röllig C; Showel MM; Strickland SA; Vives S; Tang S; Unger TJ; Joshi A; Shen Y; Alvarez MJ; Califano A; Crochiere M; Landesman Y; Kauffman M; Shah J; Shacham S; Savona MR; Montesinos P
Leuk Lymphoma; 2021 Dec; 62(13):3192-3203. PubMed ID: 34323164
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
Alexander TB; Lacayo NJ; Choi JK; Ribeiro RC; Pui CH; Rubnitz JE
J Clin Oncol; 2016 Dec; 34(34):4094-4101. PubMed ID: 27507877
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ; Breems DA; Stuessi G; van Norden Y; Bargetzi M; Biemond BJ; A von dem Borne P; Chalandon Y; Cloos J; Deeren D; Fehr M; Gjertsen B; Graux C; Huls G; Janssen JJJW; Jaspers A; Jongen-Lavrencic M; de Jongh E; Klein SK; van der Klift M; van Marwijk Kooy M; Maertens J; Michaux L; van der Poel MWM; van Rhenen A; Tick L; Valk P; Vekemans MC; van der Velden WJFM; de Weerdt O; Pabst T; Manz M; Löwenberg B;
Leukemia; 2020 Jul; 34(7):1751-1759. PubMed ID: 32020044
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
9. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
10. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Janssen J; Löwenberg B; Manz M; Bargetzi M; Biemond B; Borne PVD; Breems D; Brouwer R; Chalandon Y; Deeren D; Efthymiou A; Gjertsen BT; Graux C; Gregor M; Heim D; Hess U; Hoogendoorn M; Jaspers A; Jie A; Jongen-Lavrencic M; Klein S; Klift MV; Kuball J; Lammeren-Venema DV; Legdeur MC; Loosdrecht AV; Maertens J; Kooy MVM; Moors I; Nijziel M; Obbergh FV; Oosterveld M; Pabst T; Poel MV; Sinnige H; Spertini O; Terpstra W; Tick L; Velden WV; Vekemans MC; Vellenga E; Weerdt O; Westerweel P; Stüssi G; Norden YV; Ossenkoppele G
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562393
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
[TBL] [Abstract][Full Text] [Related]
13. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
14. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
[TBL] [Abstract][Full Text] [Related]
15. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Garzon R; Savona M; Baz R; Andreeff M; Gabrail N; Gutierrez M; Savoie L; Mau-Sorensen PM; Wagner-Johnston N; Yee K; Unger TJ; Saint-Martin JR; Carlson R; Rashal T; Kashyap T; Klebanov B; Shacham S; Kauffman M; Stone R
Blood; 2017 Jun; 129(24):3165-3174. PubMed ID: 28336527
[TBL] [Abstract][Full Text] [Related]
20. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
